POSODOBITEV Hematologija / Onkologija 2024
Kongres ESMO 2023
Datopotamab deruxtecan achieved the PFS endpoint for previously treated NSCLC. 177Lu PSMA-617 increases rPFS for metastatic castration resistant prostate cancer that is taxane-naive. Amivantamab combinations therapies are emerging as new options for EGFR mutated advanced NSCLC. Antibody-drug combinations improve outcomes for patients who have metastatic or inoperable breast cancer. Digital health technologies are revolutionising cancer care.
Uporabljate starejšo različico spletnega brskalnika, zato nekatere funkcije morda ne bodo pravilno prikazane.
MINIMALNE zahteve: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15-18, Apple Safari 7, SeaMonkey 2.15-2.23.
Viri za sestanke 19. oktober 2023 OncologyPRO zdaj ponuja vire za sestanke: +3.000 diapozitivov in spletnih oddaj; povzetki in ePlakati. Dostop do virov.
OncologyPRO zdaj ponuja vire za srečanja: +3.000 diapozitivov in spletnih oddaj; povzetki in ePlakati.
Daily ReporterDatopotamab deruxtecan reached the PFS endpoint for previously treated NSCLC23 Oct 2023TROP2-directed ADC increased PFS and reduced toxicity in comparison with chemotherapy, but the results of TROPION Lung01 are not practice changing.
TROP2-directed ADC increased PFS and reduced toxicity in comparison with chemotherapy, but the results of TROPION Lung01 are not practice changing.
Daily Reporter177Lu PSMA-617 izboljša rPFS pri bolnikih z rakom prostate, odpornih na metastatsko kastracijo, ki še niso jemali taksanov 23. oktober 2023 Ugotovitve preskušanja PSMAfore so omejene z dejstvom, da ne kažejo koristi v smislu OS.
Prijavite se za vstopnice ali kabine
Zemljevid prizorišča in hoteli v okolici
München - Holiday Inn München - središče mesta, Bavarska, Nemčija München - Holiday Inn München - središče mesta, Bavarska, Nemčija
Prijavi se